209 related articles for article (PubMed ID: 36263397)
1. Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
EClinicalMedicine; 2022 Dec; 54():101697. PubMed ID: 36263397
[TBL] [Abstract][Full Text] [Related]
2. Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.
Lee MMY; Ghouri N; McGuire DK; Rutter MK; Sattar N
Diabetes Care; 2021 May; 44(5):1236-1241. PubMed ID: 33707305
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysis.
Diallo A; Carlos-Bolumbu M; Galtier F
Acta Diabetol; 2023 Dec; 60(12):1651-1662. PubMed ID: 37439858
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials.
Lin DS; Lee JK; Hung CS; Chen WJ
Diabetologia; 2021 Dec; 64(12):2676-2686. PubMed ID: 34536085
[TBL] [Abstract][Full Text] [Related]
5. Racial, ethnic and regional differences in the effect of sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kunutsor SK; Khunti K; Seidu S
J R Soc Med; 2023 Sep; ():1410768231198442. PubMed ID: 37734450
[TBL] [Abstract][Full Text] [Related]
6. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
[TBL] [Abstract][Full Text] [Related]
8. Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.
Diallo A; Carlos-Bolumbu M; Renard PE; Galtier F
Diabetes Obes Metab; 2023 Jan; 25(1):166-176. PubMed ID: 36057779
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes.
Yanai H; Adachi H; Hakoshima M; Katsuyama H
Cardiol Res; 2023 Feb; 14(1):12-21. PubMed ID: 36896226
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
11. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2020; 14(3):181-187. PubMed ID: 32142999
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
McKee A; Al-Khazaali A; Albert SG
J Endocr Soc; 2020 May; 4(5):bvaa037. PubMed ID: 32342023
[TBL] [Abstract][Full Text] [Related]
13. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials.
Ghosh-Swaby OR; Goodman SG; Leiter LA; Cheng A; Connelly KA; Fitchett D; Jüni P; Farkouh ME; Udell JA
Lancet Diabetes Endocrinol; 2020 May; 8(5):418-435. PubMed ID: 32333878
[TBL] [Abstract][Full Text] [Related]
14. Sex differences in risk of cardiovascular events and mortality with sodium glucose co-transporter-2 inhibitors versus glucagon-like peptide 1 receptor agonists in Australians with type 2 diabetes: a population-based cohort study.
Sharma A; Wood S; Bell JS; De Blasio MJ; Ilomäki J; Ritchie RH
Lancet Reg Health West Pac; 2023 Apr; 33():100692. PubMed ID: 37181530
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits.
Marilly E; Cottin J; Cabrera N; Cornu C; Boussageon R; Moulin P; Lega JC; Gueyffier F; Cucherat M; Grenet G
Diabetologia; 2022 Dec; 65(12):2000-2010. PubMed ID: 35925319
[TBL] [Abstract][Full Text] [Related]
16. Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
Marsico F; Paolillo S; Gargiulo P; Bruzzese D; Dell'Aversana S; Esposito I; Renga F; Esposito L; Marciano C; Dellegrottaglie S; Iesu I; Perrone Filardi P
Eur Heart J; 2020 Sep; 41(35):3346-3358. PubMed ID: 32077924
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): A systematic review and meta-analysis of observational cohort studies.
Herrera Comoglio R; Vidal Guitart X
Int J Clin Pract; 2020 Sep; 74(9):e13553. PubMed ID: 32452094
[TBL] [Abstract][Full Text] [Related]
19. Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials.
Tang H; Kimmel SE; Smith SM; Cusi K; Shi W; Gurka M; Winterstein AG; Guo J
Diabetes Care; 2022 Apr; 45(4):1007-1012. PubMed ID: 35349656
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]